KNSA vs. BKV
KNSA (Kiniksa Pharmaceuticals, Ltd.) and BKV (BKV Corp) are both stocks. KNSA operates in Biotechnology (Healthcare), while BKV operates in Oil & Gas E&P (Energy). Over the past year, KNSA returned 64.38% vs 19.91% for BKV. At a 0.10 correlation, their price movements are largely independent.
Performance
KNSA vs. BKV - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, KNSA achieves a 16.00% return, which is significantly higher than BKV's -0.85% return.
KNSA
- 1D
- 1.98%
- 1M
- -16.96%
- YTD
- 16.00%
- 6M
- 17.89%
- 1Y
- 64.38%
- 3Y*
- 48.51%
- 5Y*
- 29.11%
- 10Y*
- —
BKV
- 1D
- 0.64%
- 1M
- -16.14%
- YTD
- -0.85%
- 6M
- -3.51%
- 1Y
- 19.91%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
KNSA vs. BKV - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
KNSA Kiniksa Pharmaceuticals, Ltd. | 16.00% | 108.54% | -17.45% |
BKV BKV Corp | -0.85% | 14.17% | 32.11% |
Correlation
The correlation between KNSA and BKV is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.13 |
Correlation (All Time) Calculated using the full available price history since Sep 27, 2024 | 0.10 |
Fundamentals
KNSA:
$3.94B
BKV:
$2.75B
KNSA:
$0.92
BKV:
$3.24
KNSA:
51.96
BKV:
8.31
KNSA:
5.03
BKV:
2.27
KNSA:
6.51
BKV:
1.19
KNSA:
$754.05M
BKV:
$1.08B
KNSA:
$294.06M
BKV:
$693.49M
KNSA:
$101.06M
BKV:
$544.16M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
KNSA vs. BKV — Risk / Return Rank
KNSA
BKV
KNSA vs. BKV - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Kiniksa Pharmaceuticals, Ltd. (KNSA) and BKV Corp (BKV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| KNSA | BKV | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.02 | ||
| Sortino ratioReturn per unit of downside risk | +1.47 | ||
| Omega ratioGain probability vs. loss probability | 1.30 | 1.12 | +0.18 |
| Calmar ratioReturn relative to maximum drawdown | 3.06 | 1.01 | +2.05 |
| Martin ratioReturn relative to average drawdown | 11.39 | 2.11 | +9.28 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| KNSA | BKV | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.48 | 0.46 | +1.02 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.55 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.19 | 0.63 | -0.44 |
Drawdowns
KNSA vs. BKV - Drawdown Comparison
The maximum KNSA drawdown since its inception was -83.06%, which is greater than BKV's maximum drawdown of -39.98%. Use the drawdown chart below to compare losses from any high point for KNSA and BKV.
Loading charts...
Drawdown Indicators
| KNSA | BKV | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.06% | -39.98% | -43.08% |
Max Drawdown (1Y)Largest decline over 1 year | -21.12% | -19.71% | -1.41% |
Max Drawdown (3Y)Largest decline over 3 years | -34.14% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -53.17% | — | — |
Current DrawdownCurrent decline from peak | -19.55% | -16.29% | -3.26% |
Average DrawdownAverage peak-to-trough decline | -40.26% | -11.33% | -28.93% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.67% | 9.45% | -3.78% |
Volatility
KNSA vs. BKV - Volatility Comparison
The current volatility for Kiniksa Pharmaceuticals, Ltd. (KNSA) is 10.38%, while BKV Corp (BKV) has a volatility of 11.30%. This indicates that KNSA experiences smaller price fluctuations and is considered to be less risky than BKV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| KNSA | BKV | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.38% | 11.30% | -0.92% |
Volatility (6M)Calculated over the trailing 6-month period | 33.56% | 27.73% | +5.83% |
Volatility (1Y)Calculated over the trailing 1-year period | 43.77% | 43.16% | +0.61% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 53.49% | 43.37% | +10.12% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 63.66% | 43.37% | +20.29% |
Dividends
KNSA vs. BKV - Dividend Comparison
Neither KNSA nor BKV has paid dividends to shareholders.
Financials
KNSA vs. BKV - Financials Comparison
This section allows you to compare key financial metrics between Kiniksa Pharmaceuticals, Ltd. and BKV Corp. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
KNSA vs. BKV - Profitability Comparison
KNSA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 0.00 and revenue of 214.27M. Therefore, the gross margin over that period was 0.0%.
BKV - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, BKV Corp reported a gross profit of 405.49M and revenue of 432.85M. Therefore, the gross margin over that period was 93.7%.
KNSA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 29.27M and revenue of 214.27M, resulting in an operating margin of 13.7%.
BKV - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, BKV Corp reported an operating income of 86.03M and revenue of 432.85M, resulting in an operating margin of 19.9%.
KNSA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 22.59M and revenue of 214.27M, resulting in a net margin of 10.5%.
BKV - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, BKV Corp reported a net income of 44.08M and revenue of 432.85M, resulting in a net margin of 10.2%.
Frequently Asked Questions
KNSA and BKV have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BKV has higher volatility (11.30%) compared to KNSA (10.38%). In terms of maximum drawdown, KNSA dropped -83.06% vs BKV's -39.98%.
KNSA currently has the higher Sharpe Ratio (1.48 vs 0.46), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for KNSA and BKV
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer